Why the study?
Do direct oral anticoagulants (DOACs) prevent VTE recurrence and reduce bleeding compared to conventional VTE treatment in patients with VTE without active cancer?
Do direct oral anticoagulants (DOACs) prevent VTE recurrence and reduce bleeding compared to conventional VTE treatment in patients with VTE without active cancer?
DOACs have supplanted VKAs as the recommended treatment for VTE in patients without active cancer due to comparable efficacy and reduced bleeding risk.
Supports DOAC preference in VTE; leaves open subgroup-specific long-term data needs.
The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. The DOACs are as effective for the prevention of recurrence as conventional VTE treatment, consisting of a parenteral anticoagulant followed by a VKA, and are associated with less bleeding. Because of these properties and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer. This paper examines the increasing role of the DOACs for VTE treatment.
No takes yet. Share an insight, caveat, or question.
Weitz et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: